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Summary
What is known and objective: Medication errors are a significant cause of morbidity and 
mortality especially with antineoplastic drugs, owing to their narrow therapeutic index. 
Gravimetric workflow software systems have the potential to reduce volumetric errors 
during intravenous antineoplastic drug preparation which may occur when verification 
is reliant on visual inspection. Our aim was to detect medication errors with possible 
critical therapeutic impact as determined by the rate of prevented medication errors in 
chemotherapy compounding after implementation of gravimetric measurement.
Design: A large- scale, retrospective analysis of data was carried out, related to medi-
cation errors identified during preparation of antineoplastic drugs in 10 pharmacy ser-
vices (“centres”) in five European countries following the introduction of an intravenous 
workflow software gravimetric system. Errors were defined as errors in dose volumes 
outside tolerance levels, identified during weighing stages of preparation of chemo-
therapy solutions which would not otherwise have been detected by conventional 
visual inspection.
Key results: The gravimetric system detected that 7.89% of the 759 060 doses of 
antineoplastic drugs prepared at participating centres between July 2011 and October 
2015 had error levels outside the accepted tolerance range set by individual centres, 
and prevented these doses from reaching patients. The proportion of antineoplastic 
preparations with deviations >10% ranged from 0.49% to 5.04% across sites, with a 
mean of 2.25%. The proportion of preparations with deviations >20% ranged from 
0.21% to 1.27% across sites, with a mean of 0.71%. There was considerable variation 
in error levels for different antineoplastic agents.
What is new and conclusion: Introduction of a gravimetric preparation system for 
antineoplastic agents detected and prevented dosing errors which would not have 
been recognized with traditional methods and could have resulted in toxicity or sub-
optimal therapeutic outcomes for patients undergoing anticancer treatment.
© 2017 The Authors. Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | WHAT IS KNOWN AND OBJECTIVE
Medication errors are a significant cause of morbidity and mortality 
and may occur at any stage during prescription, preparation, dispens-
ing or administration of drugs. Errors with antineoplastic drugs are 
particularly hazardous owing to their mechanism of action and narrow 
therapeutic index (TI) and the frequently poor performance status of 
cancer patients. In a retrospective analysis of mortality associated with 
medication errors, antineoplastic drugs were the second most com-
mon cause of involvement in death.1
National and international guidelines have proposed methods of 
minimizing and preventing medication errors in the clinic, pharmacy 
and patient’s home.2-4 In the pharmacy, information technology and 
automated workflow software systems have the potential to verify 
and prevent preparation and dispensing errors, such as miscalculation 
of drug concentration and incorrect use of diluent.
Traditionally, preparation of intravenous (IV) antineoplastic drugs 
has depended on the volumetric approach whereby a volume of a 
solution of a prescribed agent is withdrawn from the original vial (with 
or without prior addition of a diluent) and either administered in the 
original concentration or further diluted in a parenteral infusion solu-
tion. Checking for errors depends on real- time visual inspection or ret-
rospective review of digital images.
The introduction of the gravimetric approach to preparation of IV 
agents supported by expert software aims to reduce the potential for 
errors associated with visual inspection. At each stage of drug prepa-
ration, measured solutions are weighed on an electronic balance and 
results related to the density of the components were stored in the 
system’s database. In this way, the accuracy of the prepared volume is 
checked to ensure it falls within acceptable margins for error. Figure 1 
provides a visual comparison of the volumetric (with syringes being 
a main driver of inaccuracy [Figure 2]5) and gravimetric methods of 
preparation of prescribed doses.
European guidance supports the use of the computer- assisted 
gravimetric approach for preparation of individualized ready- to- use 
cytostatic solutions,4 and systems have been introduced in many phar-
macies in Europe. However, little research has been reported on the 
evaluation of the extent and prevalence of medication errors and their 
potential for prevention by gravimetric systems. Results of a recent 
US single- centre study using gravimetric IV workflow software system 
showed an error detection rate of 7% in 15 843 doses prepared in an 
oncology ambulatory care pharmacy, with 71% detected during grav-
imetric weighing.6
To help improve current knowledge surrounding medication er-
rors arising from preparation of oncology medicines, and to provide 
a reliable basis for the assessment of possible clinical effects, we 
carried out a large- scale, retrospective analysis of data. This related 
to medication errors identified during preparation of antineoplastic 
drugs at European pharmacies serving oncology services following 
the introduction of an IV workflow software gravimetric system (BD 
Cato™, Becton, Dickinson and Company, Franklin Lakes, NJ, USA). 
The oncology setting was chosen due to the narrow margin of safety 
for many chemotherapy solutions and the high volume of IV med-
icines specifically compounded for individual patients in dedicated 
units.
2  | METHODS
Medication errors were defined as errors in dose volumes, outside 
tolerance levels, identified during weighing stages of preparation 
of chemotherapy solutions which would not otherwise have been 
detected.
The study’s primary outcome was the number and percentage of 
doses that failed to stay within each centre’s preset tolerance limits 
for their gravimetric software systems, for dosing errors that satisfied 
local needs (Table 1). Secondary outcomes included number and pro-
portion of doses not prepared correctly at the first attempt, as well 
as number and percentage of preparations with deviations >10% and 
>20%, either above or below target dose. The study also investigated 
whether medication errors were more frequent with some types of IV 
chemotherapy.
A total of 759 060 unique preparations carried out by 245 techni-
cians working in 10 centres in five European countries (Austria, Czech 
Republic, Denmark, Germany and Switzerland) were included in this 
evaluation (Recruitment and Evaluation Process see Online appendix 
A1).
3  | RESULTS
Error tolerance levels set by centres varied from 2.5% to 6%, and the 
maximum difference in preparation tolerance was 3.5%. However, ex-
tended tolerances of up to 30% (range 3.1% to 30%) were found for 
medications that are formulated in a manner difficult to stay within 
normal limits for preparation (Table 1). Medicines most frequently 
assigned extended tolerances included bortezomib, vincristine, meth-
otrexate and cytarabine. Tolerance ranges for these and other medi-
cines were highly variable; for example, the extended tolerance for 
bortezomib at centre 6 was 3.1- 3.98, compared to 12.11- 20.63 at 
centre 9.
The proportion of antineoplastic drug samples that were outside 
centre tolerance levels ranged from 5.65% to 16.37% with an over-
all proportion of 7.89% (Table 1). The mean error rate across centres 
K E Y W O R D S
antineoplastic agents, gravimetric IV workflow software system, medication errors, preparation, 
safety
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(adjusting for unequal number of preparations at different centres) was 
10.44%. It might have been expected that centres with the lowest tol-
erance for error would have the highest error rates but, in our study, 
the centre with the lowest number of preparations out of tolerance 
(OOT) (centre 3) had one of the lowest tolerance levels. In contrast, the 
centre with the highest percentage of OOT preparations (centre 7) had 
a relatively high tolerance threshold (5%).
Excluding preparations with extended tolerances >10%, the pro-
portion of antineoplastic preparations with deviations >10% of tar-
get dose ranged from 0.49% to 5.04% across sites, with a mean of 
2.25%. The proportion of preparations with deviations >20% of target 
dose ranged from 0.21% to 1.27% across sites, with a mean of 0.71% 
(Table 2).
The centre with the highest proportion of OOT preparations (cen-
tre 7: 16.37%) also showed the poorest performance with deviations 
>10% (5.04%) and >20% (1.1%) (Tables 1 and 2).
Analysis of antineoplastic preparations compounded correctly at 
first attempt showed that 9.5% of doses were not effectively prepared 
“at the first attempt” (range 6.6% to 19%) (Table 1). The average pro-
portion of preparations requiring more than one attempt across hospi-
tals (adjusting for unequal number of preparations at different centres) 
was 13.77%. The need for repeat preparation was most common at 
centres with the highest proportion of OOT preparations.
Further analyses show that antineoplastic preparations were 
more likely to be OOT when very small amounts of drug were 
being prepared (Figure 3) and that, at most centres, levels of 
F IGURE  1 Volumetric versus 
gravimetric preparation
F IGURE  2 Tolerance of 1- and 5- mL syringes (<5 mL nominal capacity [NC]: allowed tolerance of ±5% on expelled volumes [EVs] that are 
equal to or greater than half the NC. For EVs that are less than half the NC, the tolerance obtained is ±1.5% of the NC +2% of the EV. ≥5 mL 
NC: tolerance is reduced to ±4% on EVs that are equal to or greater than half the NC, and for EVs that are less than half the NC, the tolerance is 
obtained as ±1.5% of the NC +1% of the EV)5
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dosing errors tended to be lower for drugs prepared more often 
(Figure 4).
Table 3 presents data for individual antineoplastic drugs prepared 
in the study with OOT error rates >10%. The highest error rates oc-
curred with teniposide (59.26%) and alemtuzumab (55.89%) although 
prescribing levels of these agents were low. Among the most com-
monly prepared medications, OTT rates were highest for bortezomib 
(35.4%) and vincristine (32.36%).
4  | DISCUSSION
This analysis showed that 7.89% of 759 060 doses of antineo-
plastic drugs prepared across the 10 study centres had error lev-
els outside the accepted tolerance range set by each centre; it is 
highly likely these errors would have gone undetected using tra-
ditional volumetric preparation. When this figure was adjusted to 
equally weigh the centres and their extent of service provision 
for preparation of antineoplastic agents, the mean OOT rate was 
10.44%.
TABLE  1 Error tolerance level (%), number of preparations out of tolerance (%), number of preparations not prepared correctly at first 
attempt (%) and range of extended tolerance (%) for centres in the study
Centre Tolerance for withdrawal (%) Out of tolerance (%) Not at first attempt (%)
Range of extended 
tolerance
Centre 1 4.8 11.23 18.4 4.82- 10
Centre 2 5 8.71 16.2 5.04- 25.78
Centre 3 3 5.65 8.1  
Centre 4 6 6.14 6.6 6- 25.26
Centre 5 3 12.07 13.6 3.54- 30
Centre 6 3 14.36 18.8 3.1- 20.81
Centre 7 5 16.37 19 10.17- 21.45
Centre 8 4 7.74 11.8 4.01- 14.51
Centre 9 2.5- 4 15.8 17.9 3.45- 25.92
Centre 10 5 6.27 7.2  
Total 7.89 9.5
TABLE  2 Total number and % of antineoplastic preparations with 
deviations >10% and >20% (excluding preparations with wider 
extended tolerances)
>10% (N) >10% (%) >20% (N) >20% (%)
Centre 1 1241 3.84 410 1.27
Centre 2 477 2.37 136 0.67
Centre 3 76 0.49 33 0.21
Centre 4 941 2.08 247 0.53
Centre 5 849 1.90 429 0.96
Centre 6 322 1.66 94 0.48
Centre 7 1972 5.04 430 1.10
Centre 8 247 1.41 77 0.44
Centre 9 463 2.23 188 0.90
Centre 10 7243 1.44 2424 0.48
Mean 13 831 2.25 4467 0.71
F IGURE  3 Predicted probability of preparation out of tolerance 
vs. prescribed dosage amount
F IGURE  4 Predicted probability of preparation out of tolerance 
vs. total number of preparations per centre
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The overall error level seen with antineoplastic drugs was consis-
tent with that seen for all preparations in the study (antineoplastic and 
non- antineoplastic, n=1 199 400, OOT 9%), and trends for different 
centres were also similar.
To our knowledge, this is the first large- scale retrospective re-
search that analysed data from real- time log files which record all 
events during the preparation process for IV antineoplastic drugs. This 
made it possible to apply statistical methods to describe relationships 
and deviations which occurred and identify medication errors which 
would otherwise have gone unrecognized.
The OOT error level in our study is in accordance with the 7% error 
rate identified in 15 843 IV drug doses prepared in a single oncology 
ambulatory care pharmacy in the USA;6 71% of these were detected 
gravimetrically. At the same pharmacy, 51 037 chemotherapy doses 
prepared without using the gravimetric workflow software system had 
a self- reported error rate of just 0.096% (74- fold less than with auto-
mated gravimetric software system).
All errors in our multicentre study and in the single- centre US 
study were detected during the preparation process and did not need 
to be corrected post- production. In the US study, this resulted in re-
ductions of 34% of technician production time and 37% of pharmacist 
checking time.
Although the overall OOT error rate in our study was 7.89%, five 
centres had levels >10%, the highest being >16%. Centres with the 
highest overall error rates also tended to have higher rates of “not at 
first attempt” errors and of errors >10% and >20% OOT.
Logistic regression identified significant relationships between 
OOT error rates and other recorded variables, including between 
OOT error rates and each drug’s total number of preparations 
(P<.005). With few exceptions among centres, the more often an 
individual drug was prescribed, the less likely that an OOT dosing 
error was made (Figure 4). The probability of a preparation being 
outside tolerance generally fell rapidly as the number of drug 
preparations increased over 500 preparations (measured during the 
first 10 000 preparations). A continuing decline in error rate was 
recorded at centres with highest preparation levels for individual 
drugs, reaching very low levels at centres preparing individual drugs 
≥1500 times. The reduction in dosing errors was significant (P<.05) 
for all centres except two (centre 1 P=.13 and centre 7 P=.62) and 
is likely to have reflected increased experience with preparation 
methodology.
How important are medication errors that are >10% and >20% of 
target dose? Regulatory authorities such as the European Medicines 
Agency (EMA) require that, to show bioequivalence, 90% confidence 
interval of the ratio of the area under the curve (AUC) for two drugs 
must fall within the range of 80% to 125%.2,7 For drugs with a narrow 
TI, the EMA recommends the range be 90% to 111.11%. It is there-
fore reasonable to suggest that medication deviations from 80% to 
125% for most drugs and 90% to 111.11% for those with a narrow 
TI—as is the case for many antineoplastic agents—can be considered 
problematic.
Accepted stability levels for drug preparations also provide use-
ful insights about appropriate tolerance levels for medication errors. 
Pharmaceutical scientists commonly regard a stability limit of 90% as 
acceptable.8 However, recent European guidance on practical stability 
studies of anticancer drugs draws attention to the need to consider 
TI, variability in pharmacokinetic/pharmacodynamics (PK/PD) and 
TABLE  3 Out- of- tolerance rates (N and %) and total preparations 
(N) for drugs with highest out- of- tolerance rates (only drugs with 
out- of tolerance rates >10% are shown)
International drug 
name OOT (N) Total Percentage
Teniposide 16 27 59.26
Alemtuzumab 147 263 55.89
Blinatumomab 7 14 50
Methotrexate 1274 3352 38.01
Cabazitaxel 167 464 35.99
Bortezomib 5414 15 295 35.4
Dactinomycin 34 99 34.34
Fludarabine 1284 3880 33.09
Vincristine 2580 7973 32.36
Pegaspargase 16 50 32
Asparaginase 37 147 25.17
Topotecan 2189 8969 24.41
Decitabine 92 387 23.77
Pertuzumab 629 2992 21.02
Azacitidine 6019 28 736 20.95
Cytarabine 2479 12 346 20.08
Paclitaxel formulated 
as albumin- bound 
nanoparticles
125 625 20
Pembrolizumab 25 126 19.84
Vindesine 18 99 18.18
Aflibercept 179 1007 17.78
Arsenic Trioxide 78 454 17.18
Catumaxomab 1 6 16.67
Melphalan 157 1032 15.21
Eribulin 26 172 15.12
Thiotepa 8 53 15.09
Raltitrexed 3 20 15
Docetaxel 3571 25 375 14.07
Mitomycin C 238 1709 13.93
Obinutuzumab 6 44 13.64
Cladribine 111 829 13.39




Busulfan 268 2430 11.03
Bleomycin 223 2065 10.8
Etoposide 2603 25 589 10.17
Pixantrone 6 60 10
OOT, out of tolerance.
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specific clinical use, and risks related to degradation of products. The 
guidance suggested that the classical limit of 10% of degradation may 
be inappropriate in some cases.9
The narrow TI of anticancer drugs requires exact dosing to 
obtain sufficient pharmacological activity and minimize toxic-
ity. Further, clinical effectiveness of antineoplastic regimens is 
complicated by interpatient variability, genetic polymorphisms in 
drug- metabolizing enzymes and drug- drug interactions caused by 
polymedication.10
Whereas clinical factors are difficult to control, the variability 
of pharmacological factors may be lessened by introducing sophis-
ticated methods that reduce the error margin in the preparation of 
antineoplastic agents. In our study, we found that the volumetric 
preparation method is unable to sufficiently detect the compound-
ing variability that causes preparation errors. A preparation error 
threshold of 10% was chosen for our evaluation, based on previ-
ously published studies11,12 and the Société Française de Pharmacie 
Oncologique (SFPO)/European Society of Oncology Pharmacy (ESOP) 
guidelines9 used in European countries. The German Pharmacopoeia 
DAB 10 already states in its monograph “V.5.2 Uniformity of single 
dose drugs” that for parenteral drugs, dosing deviation must stay 
within ±10% and ±15% for doses >40 and <40 mg, respectively.13 
This monograph has been replaced by the European Pharmacopoeia 
general chapters on uniformity of mass of single- dose preparations 
(2.9.5), uniformity of content of single- dose preparations (2.9.6) and 
uniformity of dosage units (2.9.40) with a more sophisticated statis-
tical approach.14
Other sources15,16 allow a variation of only 5%, based on vol-
umetric preparation processes. However, the results of this study 
demonstrate that the final doses checked by gravimetric measure-
ment are often in a range that can be very much higher than the 
assumed 5%.
With these factors in mind, oncology pharmacists may also need 
to take such parameters into account when deciding appropriate error 
tolerance levels for different antineoplastic agents.
Our study demonstrated a mean rate of deviations >10% of 
2.25% (range 0.49% to 5.04% across sites) and a mean average 
rate of deviations >20% of 0.71% (range 0.21% to 1.27% across 
sites), after excluding preparations with extended tolerances >10% 
and >20%, respectively. This suggests data retrieved from the 
gravimetric workflow system verified nearly 13 831 doses of an-
tineoplastic agents that could have been administered to patients 
at levels which may have had a negative impact on therapeutic 
outcome.
Possible therapeutic impact gains associated with the use of the 
gravimetric approach need to be considered within the context of the 
tolerance settings applied by system administrators. Standard prepa-
ration tolerances set by centres fell within a relatively narrow range 
(2.5% to 6%) with extended preparation tolerances showing much 
wider variation (3.1% to 30%).
The extended range applies to drugs whose formulation makes it 
very difficult to stay within normal limits for preparation, and gener-
ally applies to drugs requiring low volumes/masses (eg <2000 mg). The 
lower the solution mass, the higher the tolerance. The high extended 
tolerances used at some centres indicate that it may be difficult to 
achieve adequate dosing accuracy for some drugs. However, the vari-
ation in extended tolerances for some drugs, reported across centres, 
merits further investigation.
The challenge of minimizing dosing errors when working with 
very small amounts of drug is clearly demonstrated in our study 
(Figure 3). The probability of preparations being OOT fell rapidly 
as prescribed dosages increased up to 1000 mg and were almost 
zero at most centres when doses of ≥3000 mg were prepared. One 
explanation could be that drugs prepared at higher volumes con-
tain more active ingredient and require larger amounts of diluent 
during preparation. These high- volume formulations are therefore 
less likely to result in withdrawal of an incorrect dose compared with 
low- volume drugs, such as bortezomib (see extended tolerances 
above).
Tolerance levels set by centres in our study were particularly 
exceeded for certain drugs. For example, nearly 60% of teniposide 
preparations and over half of those of alemtuzumab were OOT 
(Table 3). Neither drug was commonly prescribed, so it might be con-
sidered that the high error rates were in line with another finding 
from the study that the less often an individual drug was prescribed, 
the more likely an OOT dosing error was to occur. However, as error 
rates were also high for some other more commonly prescribed 
medicines, such as bortezomib, unfamiliarity with preparation can-
not be the only reason for OOT variations for different drugs. As 
different centres used different technical equipment for preparing 
drugs, this may have influenced variability for different medicines, 
but the contribution to possible negative outcomes needs to be fur-
ther investigated.
Our findings are relevant both to centres that have already im-
plemented a gravimetric measurement system and to those still 
using traditional volumetric systems for preparing antineoplastic 
drugs, which may not achieve effective recognition of medication 
errors.
Possible limitations of our research include a lack of information 
about devices used during the preparation process and how these may 
impact on occurrence of medication errors. Variation between par-
ticipating centres in use of needles, chemospikes and safety devices 
aimed at reducing contamination due to aerosol generation may affect 
risk of medication errors.
As this was a retrospective study, we were unable to ensure stan-
dardization of preset error tolerance levels. The 3.5% difference in 
preparation tolerance between centres may have affected the varia-
tion in number of first withdrawals that are out of tolerance, but was 
not far from the aimed 2% difference.
Standardized density values for different antineoplastic drugs used 
in the study were stored in the database of the gravimetric software. 
However, as there may have been small variations in density between 
drug batches (it is not common practice for manufacturers to provide 
values with each batch), different centres may have used slightly dif-
ferent density values stored in their database at different times and 
this may have increased variations. Even so, as the maximum tolerance 
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set by any centre did not exceed 6%, this remains well below the 10% 
threshold for bioequivalence that the EMA considers relevant for 
drugs with a narrow TI.
Use of different antineoplastic agents varied across the centres in 
the study. Hence, the contribution of some centres to error rates with 
certain drugs may have been disproportional.
5  | WHAT IS NEW AND CONCLUSION
The evaluation of data from 10 centres in five European countries 
has shown that the introduction of a gravimetric preparation sys-
tem for antineoplastic agents can detect and prevent medication er-
rors which would not have been recognized by traditional methods. 
These may have caused serious toxicity or underdosing, potentially 
resulting in suboptimal outcomes for patients undergoing anticancer 
treatment.
Using logged data during gravimetric preparation of drugs, it was 
possible to identify the previously unreported dimension and potential 
impact of volume errors during medication preparation. At the same 
time, it was possible to show that a gravimetric IV workflow software 
system is capable of largely eliminating this kind of potentially life- 
threatening medication error.
The demonstration that some antineoplastic drugs are more prone 
to volume errors than others, and that errors are particularly common 
when prescribed dosages are lowest, should inform research into fu-
ture improvements in formulations.
European guidance already supports the use of the computer- 
assisted gravimetric approach for preparation of individualized 
ready- to- use cytostatic solutions,4 and obligatory implementa-
tion of gravimetric methodology for medication preparation is 
overdue.
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